Candesartan cilexetil: An update

Alexander Joost, Heribert Schunkert, Peter Walter Radke

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Introduction: Candesartan cilexetil is one of the most often-used first-line drugs regarding the management of arterial hypertension. Moreover, this drug has proven its effectiveness in chronic heart failure and exerts beneficial effects in diabetes, stroke, dementia and atrial fibrillation. Areas covered: This review focuses on the use of candesartan cilexetil in Phase II and Phase III trials and their implications for clinical usage in the treatment of arterial hypertension and heart failure. The usage of candesartan cilexetil in patients with stroke, migraine or atrial fibrillation, hypertrophy obstructive or nonobstructive cardiomyopathy and diabetic or non diabetic renal diseases will be discussed. Relevant publications were identified by an extensive Medline search. Expert opinion: Candesartan cilexetil is a highly effective ARB for the treatment of arterial hypertension and heart failure. Also, recent trials have suggested beneficial effects in diabetic patients, patients with nondiabetic renal diseases, stroke, migraine and atrial fibrillation.

Original languageEnglish
Pages (from-to)1769-1780
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number11
DOIs
StatePublished - Aug 2011
Externally publishedYes

Keywords

  • Atrial fibrillation
  • Candesartan cilexetil
  • Chronic heart failure
  • Diabetic disease
  • Hypertension
  • Migraine
  • Stroke

Fingerprint

Dive into the research topics of 'Candesartan cilexetil: An update'. Together they form a unique fingerprint.

Cite this